Democratic Republic of Congo’s Ebola outbreak has become the fastest-growing in the virus’s history, with 3,802 recorded cases and 1,707 deaths by August 4, 2026.
The Democratic Republic of Congo is confronting the largest and fastest-moving Ebola epidemic in its history. Declared on May 15, 2026, the outbreak is driven by the Bundibugyo strain of the virus—a variant for which there are no approved vaccines or standard treatments. As of Tuesday, August 4, 2026, official data recorded 3,802 cases and 1,707 deaths. The acceleration has surpassed previous historic surges, outstripping the records set during the 2018–2020 epidemic.
Epicenter in Ituri Province and Strained Treatment Capacities
Remote Ituri province in northeastern Congo remains the epicenter, accounting for nearly 90 per cent of all infections and 82.6 per cent of deaths nationwide. The disease has expanded across 49 health zones in six provinces, remaining active in 33 of them, including the major city of Kisangani. In response to the soaring caseload, humanitarian partners and international agencies are scaling up infrastructure, including the upcoming inauguration of the country’s largest treatment centre with a 100-bed capacity in Ituri, alongside a transit facility established at the Kigonze displacement camp on the outskirts of Bunia.
Yet, physical infrastructure alone cannot match the sheer velocity of transmission. During the most complete reporting week, health officials documented 567 new cases and 296 deaths in a single week—an exceptional pace of transmission that underscores the unrelenting nature of the virus, according to statements from the WorldHealth Organization.
Carl Skau, acting chief of the World Food Programme, said following a weekend visit to eastern DRC that Ebola is moving fast and hitting people already facing conflict and hunger, adding that communities are key to ending it but need support.
Armed Conflict, Displacement, and Community Mistrust Hamper Containment
Response efforts face profound operational hazards. Conflict involving armed groups, illegal mining operations, and widespread displacement have uprooted populations, leaving approximately 270,000 internally displaced people living in crowded sites across Ituri province alone. Health officials report that patient zero remains unidentified, while contact tracing has broken down significantly. Africa CDC Director-General Dr. Jean Kaseya warned during a visit to Bunia that nearly 80 per cent of new cases bypass contact tracing networks entirely, stemming instead from unmonitored spread within local communities.
Ebola Outbreak Hits Eastern DR Congo, Kills At Least 65 People | Firstpost Africa | N18G
Compounding these barriers are deep-seated community mistrust, resistance to safe burial guidelines, and security threats against medical personnel. Following the death of a patient on July 15, an attack on a hospital and treatment center in Ituri’s Nyakunde health zone forced international partner groups, including the Africa CDC and Mercy Corps, to temporarily relocate. Dr. Désiré Duabo, chief medical officer for the health zone, warned that remaining operational supplies were almost depleted following the disruption.
Health workers themselves face severe risks and professional distress. Pierre Akilimali, the Ebola response incident manager at the National Public Health Institute of the Democratic Republic of the Congo, noted that the outbreak continues to spread and it is still difficult to know when it will reach its peak. Amid unsafe conditions and unpaid wages, healthcare workers in Mongbwalu and Bunia staged protests and strikes, with local staff issuing ultimatums demanding immediate remediation.
Regional vulnerability remains high. Cross-border mobility with Uganda and South Sudan continues to challenge containment. Uganda previously declared its own territory free of Ebola in mid-June after discharging its last patient, and has dispatched experts to assist Congolese counterparts along the border.
Photo: indiatoday.in
To combat the Bundibugyo strain, clinical trials for candidate vaccines began in early July. Singapore-based Hilleman Laboratories was selected to develop the WHO-designated most promising vaccine candidate, while separate human trials commenced in the United Kingdom under Oxford University. Concurrently, enrolment has opened in Ituri for clinical studies testing two possible therapeutic treatments, offering a cautious avenue of hope as medical teams race to establish community trust and curb transmission before the outbreak reaches its peak.
Dr. Priya Deshmukh
Senior Editor, Health
Dr. Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.
